-
1Academic Journal
Συγγραφείς: A. V. Vorobev, V. O. Bitsadze, A. G. Solopova, J. Kh. Khizroeva, D. O. Utkin, D. О. Ostrikov, D. V. Blinov, J.-C. Gris, I. Elalamy, G. Gerotziafas, A. D. Makatsariya, А. В. Воробьев, В. О. Бицадзе, А. Г. Солопова, Д. Х. Хизроева, Д. О. Уткин, Д. О. Остриков, Д. В. Блинов, Ж.-К. Гри, И. Элалами, Г. Геротзиафас, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 19, No 4 (2025); 476-487 ; Акушерство, Гинекология и Репродукция; Vol 19, No 4 (2025); 476-487 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: тромбопрофилактика, vWF, ADAMTS-13, vWF/ADAMTS-13 ratio, venous thromboembolic events, gynecologic oncology patients, chemotherapy, anticoagulant therapy, ACT, endothelial dysfunction, hemostasis, low molecular weight heparins, prognostic marker, thromboprophylaxis, соотношение vWF/ADAMTS-13, венозные тромбоэмболические осложнения, онкогинекологические пациентки, химиотерапия, антикоагулянтная терапия, АКТ, эндотелиальная дисфункция, гемостаз, низкомолекулярные гепарины, прогностический маркер
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2548/1378; Xu W., Tan X., Li M.L. et al. Von Willebrand factor and hematogenous cancer metastasis under flow. Front Cell Dev Biol. 2024;12:1435718. https://doi.org/10.3389/fcell.2024.1435718.; Rayner S.G., Scholl Z., Mandrycky C.J. et al. Endothelial-derived von Willebrand factor accelerates fibrin clotting within engineered microvessels. J Thromb Haemost. 2022;20(7):1627–37. https://doi.org/10.1111/jth.15714.; Dong J.F., Moake J.L., Nolasco L. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 20021;100(12):4033–9. https://doi.org/10.1182/blood-2002-05-1401.; Muia J., Zhu J., Gupta G. et al. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014;111(52):18584–9. https://doi.org/10.1073/pnas.1413282112.; Obermeier H.L., Riedl J., Ay C. et al. The role of ADAMTS-13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost. 2019;3(3):503–14. https://doi.org/10.1002/rth2.12197.; Colonne C.K., Favaloro E.J., Pasalic L. The intriguing connections between von Willebrand factor, ADAMTS13 and cancer. Healthcare (Basel). 2022;10(3):557. https://doi.org/10.3390/healthcare10030557.; Ayan D., Bozkurt Polat Ş.B., Bayram E. et al. A comparative analysis of the roles of von Willebrand factor and ADAMTS13 in hepatocellular carcinoma: a bioinformatics and microarray-based study. Curr Issues Mol Biol. 202547(4):270. https://doi.org/10.3390/cimb47040270.; Guo R., Yang J., Liu X. et al. Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer. J Clin Lab Anal. 2018;32(1):e22219. https://doi.org/10.1002/jcla.22219.; Turner N.A., Nolasco L., Ruggeri Z.M., Moake J.L. Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood. 2009;114(24):5102–11. https://doi.org/10.1182/blood-2009-07-231597.; Setiawan B., Permatadewi C.O., de Samakto B. et al. Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thromb J. 2020;18(1):33. https://doi.org/10.1186/s12959-020-00247-6.; Pépin M., Kleinjan A., Hajage D. et al. ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. J Thromb Haemost. 2016;14(2):306–15. https://doi.org/10.1111/jth.13205.; Feng Y., Li X., Xiao J. et al. ADAMTS13: more than a regulator of thrombosis. Int J Hematol. 2016;104(5):534–9. https://doi.org/10.1007/s12185-016-2091-2.; Comerford C., Glavey S., Quinn J., O'Sullivan J.M. The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. J Thromb Haemost. 2022;20(8):1766–77. https://doi.org/10.1111/jth.15773.; Shahidi M. Thrombosis and von Willebrand Factor. Adv Exp Med Biol. 2017;906:285–306. https://doi.org/10.1007/5584_2016_122.; Sasano T., Gonzalez-Delgado R., Muñoz N.M. et al. Podoplanin promotes tumor growth, platelet aggregation, and venous thrombosis in murine models of ovarian cancer. J Thromb Haemost. 2022;20(1):104–14. https://doi.org/10.1111/jth.15544.; Vorobev A., Bitsadze V., Yagubova F. et al. The phenomenon of thrombotic microangiopathy in cancer patients. Int J Mol Sci. 2024;25(16):9055. https://doi.org/10.3390/ijms25169055.; Karampinis I., Nowak K., Koett J. et al. Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality. Haematologica. 2023;108(1):261–6. https://doi.org/10.3324/haematol.2022.281315.; Mulder F.I., Candeloro M., Kamphuisen P.W. et al.; CAT-prediction collaborators. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277–87. https://doi.org/10.3324/haematol.2018.209114.; Muñoz Martín A.J., Ortega I., Font C. et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(8):1056–61. https://doi.org/10.1038/s41416-018-0027-8.; van Es N., Di Nisio M., Cesarman G. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102(9):1494–501. https://doi.org/10.3324/haematol.2017.169060.; Dickson K., Koom-Dadzie K., Brito-Dellan N., Escalante C. Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT): a narrative review. Support Care Cancer. 2022;30(10):8539–45. https://doi.org/10.1007/s00520-022-07160-w.; https://www.gynecology.su/jour/article/view/2548